Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

as “no two people living with gMG experience the disease in the same way.” “The approval of rozanolixizumab […] means doctors have an additional approved treatment option for their gMG ...

Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...

MG is a rare and chronic autoimmune disease where IgG antibodies disrupt ... States and 20,000 people in Japan with living with gMG. The Phase 2b trial is a dose range-finding, double-blinded ...

Amsterdam, the Netherlands— (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...